Scientists propose rebalancing the GPCR receptor family, which 40 percent of drugs already target, to delay several diseases of aging at the same time.
Sources indicate that heart disease, type 2 diabetes, and Alzheimer’s are often associated with aging. They get treated as three different problems, by three different specialists, with three different sets of pills.
To a group of pharmacologists, that is the wrong way of thinking.
The three diseases share a handful of aging processes, and those processes run through one family of receptors on the surface of cells. Nearly 40 percent of today’s drugs already act on that family.
The scientists propose treating the family as one network and nudging it back toward a younger balance, so that several diseases of aging are delayed at once.
It has been revealed that it’s a proposal rather than an experiment. The paper reviews what is known about these receptors and lays out a blueprint. No drug or combination of drugs has been tested against aging in this way.
Stuart Maudsley of the Moffitt Cancer Center in Tampa, Florida, is the senior author, with nine co-authors in the United States, Britain, and Canada.
Recent findings suggest that in an interview with Earth.com, he stated the case rests on practicality rather than on proof. “Our argument is not that GPCRs have already been shown to outperform every other approach,” he said.
“It is that they offer an unusually practical set of entry points into this interconnected biology, because we already know how to target many of them with medicines.”.
The receptors are called G protein-coupled receptors, or GPCRs. Each one sits in a cell’s outer membrane and passes a message from outside the cell to the machinery inside.
The message might come from a hormone, a nerve signal, or a nutrient. Humans have roughly 800 of them in five families, and about 720 belong to the largest family.
It has been revealed that many familiar medicines work on these receptors, each prescribed for one disease. Beta blockers for heart failure and blood pressure drugs that block angiotensin act on them.
So do the Parkinson’s drug istradefylline and the diabetes and weight-loss drugs semaglutide and tirzepatide.
According to recent reports, maudsley compared the body to a transport network. Repairing one road helps, he said, but it may not clear congestion caused by problems across the wider system.
In the same way, treating one disease pathway can be valuable without fixing the linked disturbances that leave a person open to several other conditions of aging.
The paper’s central observation is that the five families, which differ widely in structure, age in the same way. Cells carry fewer of the protective receptors on their surface.
The receptors end up in the wrong place inside the cell, their signaling weakens, and the subtypes that drive inflammation become more stable or more numerous.
The authors tie those changes to the standard list of aging’s hallmarks: chronic low-level inflammation, failing mitochondria, DNA damage, worn-out protein maintenance, and the exhaustion of stem cells.
The list also includes the buildup of senescent cells, which stop dividing but keep sending out inflammatory signals.
It has been revealed that in the authors’ reading, the decline of this receptor family accounts for many of those hallmarks. The evidence behind that ranges from approved drugs to animal and cell studies.
That is the part Maudsley called most interesting. Very different receptor families, he mentioned, connect to the same problems in aging, and that convergence is what makes a network therapy worth testing.
Industry observers note that the proposal is not to turn the receptors up. “Crucially, this is not about switching all GPCR activity up or down,” Maudsley said.
“Some signals may need strengthening, others restraining, and the right balance will depend on the tissue and the individual. Precision, rather than blanket stimulation, is the central idea.”.
Sources indicate that the authors describe several tools. One is a drug that triggers only part of a receptor’s response. Another binds a receptor at a second site to tune it rather than switch it.
According to recent reports, A third is a single molecule that acts on several receptors at once. A computer model of an individual patient’s biology would help choose among them.
They also propose pairing receptor drugs with other anti-aging treatments, such as drugs that clear senescent cells or improve metabolism.
The authors wrote that this could be “the greatest leap in medicine since antibiotics.” They also wrote that biology may never offer a cure for everything.
Industry observers note that asked by Earth.com what the first test would be, Maudsley described a small one. Take an aged animal model. One group gets a treatment that supports metabolic resilience, another gets a treatment that limits persistent inflammation, and a third gets both.
Then measure physical function, metabolic control, and tissue health rather than a single lab marker.
The combination would have to beat either treatment alone, and the team would also need evidence that the benefit ran through the receptor network they meant to change.
Sources indicate that if it did, he noted, the next step would be a randomized trial in a defined patient group. That trial would test whether the network can be influenced safely in people, which is not the same as claiming to have slowed human aging.
It has been revealed that maudsley told Earth.com he expects the field to deliver on its goal of more healthy years within five to ten years, given the pace of computational biology. That is his forecast; the paper sets no date.
Sources indicate that the paper names its own limits. Part of aging is the slow buildup of random copying errors in DNA, and the authors wrote that no treatment has been shown to reduce that error rate. Their strategy aims at what cells do in response to the damage, not at the damage itself.
Many GPCRs bind several different molecules and set off several signals, which makes a clean, selective drug hard to design.
Recent findings suggest that for gene-based approaches, getting the treatment into most tissues is an unsolved problem. And stimulating stem cells to repair tissue could raise the risk of cancer.
It has been revealed that two of the authors have a commercial stake. Silke Dodel co-founded AstraNexa and founded Deep Science, two companies in Boca Raton, Florida, and Roza Bejanyan works for AstraNexa.
The other authors are at Moffitt, the Department of Pharmacology at the University of Cambridge, McGill University, and Florida Atlantic University.
Whether rebalancing a receptor network delays even two of these diseases of aging at the same time in an animal is the open question. The combination experiment Maudsley laid out is where an answer would start.
The full study was published in the journal Frontiers in Science.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
